Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant
Status:
Withdrawn
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Type 1 diabetes mellitus (T1D) is an autoimmune disease in which the insulin-producing
pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of
this study is to assess the safety and effectiveness of low molecular weight sulfated dextran
(LMW-SD) on post-transplant islet function in people with T1D who have responded to intensive
insulin therapy and have received kidney transplants. This study is taking place in Uppsala
and Stockholm, Sweden, and Oslo, Norway.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)